Document is current
Any future updates will be listed below
-
Authors
Panizo-Inogés, María https://orcid.org/0009-0001-1918-7675
Marcos-Jubilar, María
González-Porras, Jose Ramón
Puerta-Vazquez, Carlos
Fernández-Arias, Clara
Rodríguez-Otero, Paula
Alfonso-Pierola, Ana
Villar, Sara
Canales, Miguel Ángel
Orbe, Josune
Páramo, Jose Antonio
Prósper, Felipe
Lecumberri, Ramón
-
Funding
Funding for this research was provided by:
Junior Clinical Grant in the AECC Territory 2022, Scientific Foundation of the Spanish Association Against Cancer.
López-Borrasca Award, Spanish Society of Thrombosis and Hemostasis, 2023.
Grant from the 2023 Call for R&D&I Projects in Health, Carlos III Health Institute (PI23/00890)
Universidad de Navarra
- License Information
-
More Information
Article History
Received: 6 November 2025
Accepted: 16 March 2026
First Online: 31 March 2026
Declarations
:
: Paula Rodríguez-Otero: Honoraria from lectures: BMS-Celgene, J&J Innovative Medicines, Sanofi, GSK, Regeneron, Pfizer. Participation in Ad Board meetings: BMS, Janssen, Sanofi, Oncopeptides, Pfizer, Roche, Regeneron, H3 Biomedicine and GSK. Consultant: BMS-Celgene, Abbvie, Roche, J&J Innovative Medicines, and Pfizer. Research funding: Pfizer. Travel Support: Pfizer—Ana Alfonso: Honoraria from lectures: Novartis, BMS, Abbvie, Jazz Pharma, Janssen, Astellas. Participation in Ad Board meetings: BMS, Syros, Jazz Pharma, Otsuka, Ascentage Pharma, Janssen. Consultant: Astellas, Jazz Pharma; Janssen. Research Founding: Astra Zeneca—Miguel Ángel Canales: Speaker fees: Abbvie, Gilead/Kite, Incyte, J&J, Miltenyi, MSD, Roche, Takeda. Consulting or Advisory role: Beigene, Genmab, Gilead/Kite, Incyte, J&J, Lilly, Miltenyi, Roche, Takeda. Travel & Accommodations: Gilead/Kite, J&J, Roche, Takeda. There are no other conflict of interest to disclose.
: The study was approved by the local ethics committee and conducted in accordance with the Declaration of Helsinki.
: All participants provided written informed consent prior to inclusion.
